On August 21, 2026, Edesa Biotech, Inc. (“Edesa Biotech”), a Canadian clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, completed a US$25 million public offering of common shares, common share purchase warrants, and pre-funded warrants pursuant to an underwritten public offering.
The offering was underwritten by Guggenheim Securities, LLC as sole bookrunner. Edesa Biotech plans to use the net proceeds from the offering for general corporate purposes, which may include working capital, capital expenditures and research and development and manufacturing expenses.
Fasken advised Edesa Biotech on the Canadian law aspects of the transaction with a team comprised of Wojtek Baraniak, Myroslav Chwaluk, and Barbara Clark.
Jurisdiction
- Ontario
